Sage Therapeutics shares soar after postpartum depression drug meets main goal

Sage says the drug, brexanolone, achieved lower rates of depression in patients compared with a placebo in both trials.
Source: CNBC

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>